Study on Drug Interaction of HRS-1780 Tablets, Henagliflozin Tablets, Metformin Tablets and HRS-7535 Tablets in Healthy Human

NCT ID: NCT06495931

Last Updated: 2024-07-11

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-07-31
• Study Completion Date: 2024-07-31

Brief Summary

This study was designed as a single-center, single-arm, open, fixed-sequence, self-controlled trial in healthy subjects.

Conditions

Type 2 Diabetes Mellitus

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment group A: HRS-1780 tablets、HR20033 tablets、HRS-7535 tablets

Group Type: EXPERIMENTAL

HRS-1780 tablets

Intervention Type: DRUG

HRS-1780 tablets, three times

HR20033 tablets

Intervention Type: DRUG

HR20033 tablets, nine times

HRS-7535 tablets

Intervention Type: DRUG

HRS-7535 tablets ，three times or nine times

Interventions

HRS-1780 tablets

HRS-1780 tablets, three times

Intervention Type: DRUG

HR20033 tablets

HR20033 tablets, nine times

Intervention Type: DRUG

HRS-7535 tablets

HRS-7535 tablets ，three times or nine times

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Voluntarily sign informed consent before the start of activities related to this experiment, be able to communicate well with the investigators, understand the procedures and methods of this experiment, and be willing to strictly follow the clinical trial protocol to complete this experiment;

2. Healthy male aged 18-50 years old (including both ends of the value, subject to the signing of the informed consent);

3. Weight ≥ 50 kg, and body mass index (BMI): 22~26 kg/m2 (including both ends of the value);

4. Signed informed consent to have no birth plan for 6 months after the last dose, and agreed to take effective contraceptive measures.

Exclusion Criteria

1. Have a history of drug or food allergy, or are allergic;

2. inability to swallow, chronic diarrhea and intestinal obstruction, or the presence of multiple other factors affecting the administration and absorption of drugs;

3. QTcF > 450 ms was detected by 12-lead electrocardiogram during screening or there were other abnormalities that were clinically significant as determined by the investigator;

4. Hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, syphilis antibody test positive;

5. Those who smoked more than 5 cigarettes per day in the 3 months prior to screening and could not stop using any tobacco products during the test

6. Regular drinkers in the 6 months prior to screening, i.e. those who drink more than 14 units of alcohol per week (1 unit = 285 mL for beer, or 25 mL for spirits, or 100 mL for wine) and cannot stop using any alcohol-containing products during the test period, who test positive for alcohol breath test;

7. Patients with a history of drug abuse, drug dependence (consultation) or positive urine drug abuse screening before drug administration;

8. Patients who have received any surgery within 6 months before screening;

9. Participants who have participated in clinical trials of any drug or medical device within 3 months prior to screening (subject to receiving experimental drugs or medical device intervention);

10. Blood donation (or blood loss) and blood donation (or blood loss) ≥ 400 mL within 3 months before screening, or receiving blood transfusion;

11. Patients who had any clinically significant acute disease within 1 month before screening;

12. People who have taken any prescription, over-the-counter, Chinese herbal or health product within 14 days prior to taking the study drug, and plan to take any drug or health product other than the study drug during the trial;

13. Patients with a history of severe hypoglycemia;

14. People with a history of recurrent urinary tract infections, diabetes insipidus or/and genital fungal infections;

15. Prior to screening, gastrointestinal surgery that can lead to malabsorption, or long-term use of drugs that have a direct effect on gastrointestinal motility. Have undergone bariatric surgery or procedures (such as gastric banding), or have used drugs with weight reduction effects (including but not limited to orlistat) in the 3 months prior to administration, or have experienced a weight change of more than 10% in the 3 months prior to administration;

16. Use of drugs that may affect glucose metabolism (e.g. systemic steroids, non-selective beta-blockers, monoamine oxidase inhibitors) or/and exposure to metformin and/or SGLT2 inhibitors within 1 month prior to screening;

17. Previous history of clinical gastric emptance abnormalities (such as gastric outlet obstruction), severe chronic gastrointestinal diseases (such as inflammatory bowel disease, active ulcers);

18. Previous history or family history of medullary thyroid cancer, multiple endocrine adenomatosis type 2, previous history of pancreatitis or symptomatic gallbladder disease;

19. 48 h before the first dose until the end of the study, subjects refused to stop drinking or eating foods with high methylxanthine content, such as coffee, tea, cola, chocolate, etc.; For 7 days prior to the first dose until the end of the study, subjects refused to discontinue any beverage or food containing grapefruit; Those who have special dietary requirements and cannot comply with a unified diet;

20. Physical examination, vital signs, laboratory examination, abdominal ultrasound, chest film and other abnormal and clinically significant examination results;

21. Persons who have been vaccinated within 1 month prior to screening or plan to be vaccinated during the trial period;

22. Subjects with other factors deemed unsuitable for participation in the study by the investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Xuanwu Hospital ,Capital Medical University

Beijing, Beijing Municipality, China

Countries

China

Central Contacts

Sheng Feng

Role: CONTACT

sheng.feng@hengrui.com

+86-0518-82342973

Facility Contacts

Lan Zhang

Role: primary

Other Identifiers

HRS-7535-105

Identifier Type: -

Identifier Source: org_study_id